Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non–Small Cell Lung Cancer
M Ohgami, T Kaburagi, A Kurosawa… - Therapeutic drug …, 2018 - journals.lww.com
Background: Erlotinib is used for treating non–small cell lung cancer (NSCLC). Intestinal
absorption of erlotinib is impaired under gastric pH elevation; therefore, coadministration of …
absorption of erlotinib is impaired under gastric pH elevation; therefore, coadministration of …
Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: a phase 1/2 single-group open-label trial
Importance The combination of erlotinib and bevacizumab as initial treatment of epidermal
growth factor receptor (EGFR [OMIM131550])–mutant lung cancers improves progression …
growth factor receptor (EGFR [OMIM131550])–mutant lung cancers improves progression …
Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung …
T Hirose, K Fujita, S Kusumoto, Y Oki, Y Murata… - Lung Cancer, 2016 - Elsevier
Objectives Gefitinib is a potent epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor and is a key drug for patients with EGFR mutation-positive advanced non-small cell …
inhibitor and is a key drug for patients with EGFR mutation-positive advanced non-small cell …
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
W Zhang, Y Wei, D Yu, J Xu, J Peng - BMC cancer, 2018 - Springer
Background The first-generation epidermal growth factor receptor tyrosine kinase inhibitors
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …
Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis
Y Zhao, B Cheng, Z Chen, J Li, H Liang, Y Chen… - Critical Reviews in …, 2021 - Elsevier
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are treatments
commonly used for lung cancer. The toxicity profile including toxicity incidence, severity, and …
commonly used for lung cancer. The toxicity profile including toxicity incidence, severity, and …
The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review
XW Yang, K Yang, KY Kuang - Current oncology reports, 2014 - Springer
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been
extensively investigated in previously treated advanced non-small-cell lung cancer …
extensively investigated in previously treated advanced non-small-cell lung cancer …
Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer
Y Saito, Y Takekuma, M Kobayashi… - European Journal of …, 2021 - Springer
Purpose Gefitinib is one of the standard treatments for non-small cell lung cancer (NSCLC)
with epidermal growth factor receptor mutations. It has been reported that acid suppressants …
with epidermal growth factor receptor mutations. It has been reported that acid suppressants …
First-or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
ACC Huang, CH Huang, JS Ju… - Therapeutic …, 2021 - journals.sagepub.com
Background: There are limited comparisons of first-and second-generation EGFR tyrosine
kinase inhibitors (TKIs) in large, real-world cohorts of non-small cell lung cancer (NSCLC) …
kinase inhibitors (TKIs) in large, real-world cohorts of non-small cell lung cancer (NSCLC) …
Chemotherapy plus EGFR-TKI as first-line treatment provides better survival for advanced EGFR-positive lung adenocarcinoma patients: updated data and exploratory …
Y Lou, J Xu, Y Zhang, J Lu, T Chu, X Zhang, H Wang… - Targeted Oncology, 2020 - Springer
Background Previously, we demonstrated that treatment with gefitinib combined with
pemetrexed plus carboplatin chemotherapy improved progression-free survival (PFS) …
pemetrexed plus carboplatin chemotherapy improved progression-free survival (PFS) …
Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non‑small cell lung cancer: A network meta‑analysis
Y Liu, Y Zhang, G Feng, Q Niu… - Experimental and …, 2017 - spandidos-publications.com
The present network meta‑analysis aimed to compare the effectiveness and adverse effects
of gefitinib, erlotinib and icotinib in the treatment of patients with non‑small cell lung cancer …
of gefitinib, erlotinib and icotinib in the treatment of patients with non‑small cell lung cancer …